Award for Bilobil in Poland

The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.

The award was based on voting by the Polish people. Bilobil turned out to be the most popular drug for memory improvement in Poland. This year Bilobil was also appreciated by pharmacists who awarded it The Product of the Year 2007 within the products for memory improvement. So it appears that Bilobil is the most highly evaluated drug in its group by patients and specialists.

Bilobil was frequently selected by the Polish pharmacists and patients who in the last year awarded it a gold "Consumer's Laurel".

Bilobil was also twice awarded a statuette of Golden Otis.

Bilobil is a drug that contains natural Ginkgo biloba leaf substances which improve the metabolism in brain cells and the supply of oxygen to the brain. The active substances of the extract improve memory and concentration, and are beneficial for life energy. The clinical examination* which was carried out in Otolaryngology Clinic Collegium Medicum in Bydgoszcz proved that the drug improves brain functions, such as memory and the ability to concentrate. Bilobil also efficiently prevents dizziness and tingling in the ears. In 2004 the producer enriched the Bilobil brand in Poland by a new product. Bilobil forte contains a double dose of Ginkgo biloba extracts (80 mg) and is intended for the active part of the population enabling a longer and a more intensive mental effort.

About Krka
Krka is one of the top generic pharmaceutical companies in Europe. For further information, please visit www.krka.si.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]